Zoetis Inc (NYSE:ZTS) EVP Kristin C. Peck Sells 11,500 Shares

Zoetis Inc (NYSE:ZTS) EVP Kristin C. Peck sold 11,500 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $117.16, for a total transaction of $1,347,340.00. Following the completion of the transaction, the executive vice president now owns 44,877 shares in the company, valued at $5,257,789.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of ZTS traded up $1.67 on Friday, reaching $117.92. 3,348,676 shares of the company’s stock were exchanged, compared to its average volume of 2,383,347. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $56.09 billion, a P/E ratio of 37.67, a price-to-earnings-growth ratio of 2.87 and a beta of 0.88. The business has a 50 day moving average price of $124.63 and a two-hundred day moving average price of $116.88. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $130.20.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. Zoetis’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.83 earnings per share. Equities research analysts predict that Zoetis Inc will post 3.6 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is 21.09%.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tarbox Family Office Inc. raised its stake in shares of Zoetis by 74.4% during the third quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock worth $27,000 after buying an additional 93 shares during the last quarter. JJJ Advisors Inc. bought a new stake in Zoetis in the second quarter valued at approximately $25,000. Prestige Wealth Management Group LLC bought a new stake in Zoetis in the second quarter valued at approximately $27,000. Tradewinds Capital Management LLC bought a new stake in Zoetis in the third quarter valued at approximately $31,000. Finally, Altshuler Shaham Ltd increased its stake in Zoetis by 198.8% in the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after purchasing an additional 169 shares in the last quarter. 89.97% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on ZTS. Credit Suisse Group set a $138.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, October 11th. Argus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Craig Hallum upped their target price on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, SunTrust Banks upped their target price on shares of Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday, August 13th. Eight investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $126.75.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: What Does a Sell-Side Analyst Rating Mean?

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.